ENSYSCE BIOSCIENCES INC (ENSC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.46+3.57%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ENSC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -88.4% |
| Our one-year growth estimate | diamond | -35.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 52.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ENSC — CEO transition
Dated 2026-08-06
President — Lynn Kirkpatrick: Lynn Kirkpatrick resigned from her position as President due to the Merger Agreement.
Why it matters: Getting more people to join the study is important for PF614-MPAR.
Supportive ifEnrollment reaches 75% or more of the target for the PF614-MPAR Phase 3 trial.
Worry ifEnrollment stalls or drops below 50% of the target for the PF614-MPAR Phase 3 trial.
Why it matters: Results from this review could lead to partnerships or licensing deals that enhance growth potential.
Watch forA partnership or licensing deal was announced after the review of options.
Also watch forNo new partnerships or licensing deals were announced after the review.
Why it matters: Partnerships could speed up Ensysce's work and help with money issues.
Supportive ifA new partnership or licensing deal will help advance TAAP or MPAR technologies.
Worry ifNo new partnerships or licensing deals will be announced in the next quarter.
Why it matters: Successful capital raises are important. They help fund operations and growth plans.
Watch forThe company announces a successful capital raise. It may also share new investor agreements.
Also watch forThere are no updates on capital raises or investor agreements. This is concerning.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$351 on $10,000 · ±3.5% | How much price usually moves either way. |
| Bad day | $1,139 loss on $10,000 · 11.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,023 loss on $10,000 · 90.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Approval is needed to change to common stock. This affects capital and future funding.
Supportive ifStockholders agreed to change Series C Preferred Stock to common stock.
Worry ifStockholders did not approve the change of Series C Preferred Stock.
Why it matters: Stabilizing or growing revenue means that efforts to make money are working.
Supportive ifQ2 revenue was above $0.96 million. This shows improvement from Q1.
Worry ifQ2 revenue is still below $0.96 million. This shows ongoing challenges.
Why it matters: High cash burn may mean financial trouble and affect future operations. Investors may worry about staying power.
Worry ifCash burn in Q3 2026 is reported below $5 million.
Less concerning ifCash burn in Q3 2026 exceeds $5 million.
Why it matters: Topline data will show if CY200 can effectively treat Complex Regional Pain Syndrome. This is crucial for future funding and development.
Supportive ifThe Phase 2 trial shows strong results in treating CRPS symptoms.
Worry ifData from the Phase 2 trial shows no significant efficacy for CY200.
Why it matters: Better cash flow is key for keeping operations running and funding clinical trials. It shows better financial health.
Supportive ifCash flow from operations turns positive in Q2 2026. This shows better financial management.
Worry ifCash flow from operations stays negative in Q2 2026. This shows ongoing financial strain.
Why it matters: Interim data will show if PF614 can deliver effective pain relief with abuse protection. This is key for future approval.
Supportive ifInterim data from the PF614-301 trial shows strong pain relief with low abuse risk.
Worry ifInterim data does not show good pain relief or shows high abuse risk.
Why it matters: Better cash flow is important for keeping operations running and funding trials. It shows financial health.
Supportive ifQ2 earnings show a reduction in operating losses or positive cash flow.
Worry ifThe Q2 earnings report shows negative cash flow. It also shows larger operating losses.
Why it matters: Topline data will show if CY200 can effectively treat Complex Regional Pain Syndrome. This is crucial for future funding and development.
Supportive ifThe Phase 2 trial shows that CY200 works well and is safe.
Worry ifThe Phase 2 trial does not show that CY200 works or is safe.